Immune checkpoint inhibitors (ICIs) are antineoplastic agents associated with a multitude of immune-related adverse events (irAEs). Available data from clinical trials include highly selective patient populations which may limit their applicability to real-world clinical practice.
Methods
We present a retrospective cohort study of cancer patients treated with ICI therapy at the Zablocki VA Medical Center between 2014 and 2021. Information on demographics, cancer diagnosis, type of therapy, treatment duration, comorbidities, irAE type, and overall survival were collected.
Results
We identified 187 patients who received at least one dose of ICI. About half the patients experienced at least one irAE, the most common categories being fatigue, pulmonary, and endocrine irAEs. Approximately half of the irAEs were diagnosed within the first three months of starting ICI therapy, and 60.38% of those who experienced irAEs discontinued ICI therapy. Patients who experienced endocrine or intestinal irAEs had a significantly longer overall survival.
Conclusion
Immune-related complications due to ICI therapy are common and can frequently lead to treatment discontinuation in the real-world setting. Endocrine and intestinal irAEs may correlate with improved survival. The ICI-treated patients who received palliative radiation therapy to the bone had less irAEs, possibly due to immunogenic cell death.
Ramos-CasalsMBrahmerJRCallahanMK, et al.Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers2020; 6: 38.
2.
HowladerNForjazGMooradianMJ, et al.The effect of advances in lung-cancer treatment on population mortality. N Engl J Med2020; 383: 640–649.
3.
ChoiJLeeSY. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw2020; 20: e9.
4.
KhanSGerberDE. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review. Semin Cancer Biol2020; 64: 93–101.
5.
KhojaLDayDWei-Wu ChenT, et al.Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol2017; 28: 2377–2385.
6.
MartinsFSofiyaLSykiotisGP, et al.Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol2019; 16: 563–580.
7.
LawsonDH. Postmarketing surveillance versus clinical trials: which benefits the patient?Cardiology1994; 85: 18–23.
8.
KimHSLeeSKimJH. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci2018; 33: e213.
9.
TempletonAJVera-BadilloFEWangL, et al.Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol2013; 24: 2972–2977.
10.
AlmutairiARMcBrideASlackM, et al.Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis. Front Oncol2020; 10: 91.
11.
FuhrmannCStruckJPIvanyiP, et al.Checkpoint inhibition for metastatic urothelial carcinoma after chemotherapy-real-world clinical impressions and comparative review of the literature. Front Oncol2020; 10: 08.
12.
Guzman-PradoYBen ShimolJSamsonO. Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis. Cancer Immunol Immunother2021; 70: 89–100.
13.
OlefskyJMGlassCK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol2010; 72: 219–246.
14.
SpainLDiemSLarkinJ. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev2016; 44: 51–60.
15.
HryniewickiATWangCShatskyRA, et al.Management of immune checkpoint inhibitor toxicities: a review and clinical guideline for emergency physicians. J Emerg Med2018; 55: 489–502.
16.
MelsonJReedDHortonBJ, et al.Immune-related adverse events in advanced NSCLC treated with immunotherapy alone or concurrent chemotherapy and immunotherapy. J Clin Oncol2019; 37: 83–83.
17.
WangCQiaoWJiangY, et al.The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis. J Cell Physiol2020; 235: 4913–4927.
18.
BorghaeiHPaz-AresLHornL, et al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med2015; 373: 1627–1639.
19.
MansfieldASHerbstRSde CastroGJr., et al.Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1-positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, 010, 024, and 042. JTO Clin Res Rep2021; 2: 100205.
20.
EggermontAMMKicinskiMSuciuS. Management of immune-related adverse events affecting outcome in patients treated with checkpoint inhibitors – reply. JAMA Oncol2020; 6: 1301.
21.
GarassinoMCChoBCKimJH, et al.Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol2018; 19: 521–536.
22.
HerbstRSGaronEBKimDW, et al.Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC. J Thorac Oncol2021; 16: 1718–1732.
23.
NoronhaVAbrahamGPatilV, et al.A real-world data of immune checkpoint inhibitors in solid tumors from India. Cancer Med2021; 10: 1525–1534.
24.
EditorialO. Erratum to combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer. Transl Lung Cancer Res2022; 11: 504–505.
25.
WangZWeiLLiJ, et al.Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer. Transl Lung Cancer Res2021; 10: 4368–4379.
26.
WangFYangSPalmerN, et al.Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types. NPJ Precis Oncol2021; 5: 82.
27.
MohamadODiaz de LeonASchroederS, et al.Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. Oncoimmunology2018; 7: e1440168.
28.
KrausKMFischerJCBormKJ, et al.Evaluation of practical experiences of German speaking radiation oncologists in combining radiation therapy with checkpoint blockade. Sci Rep2021; 11: 7624.
29.
NakajimaNKanoTOdaK, et al.Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma. IJU Case Rep2020; 3: 215–218.
30.
MattesMDEubankTDAlmubarakM, et al.A prospective trial evaluating the safety and systemic response from the concurrent use of radiation therapy with checkpoint inhibitor immunotherapy in metastatic non-small cell lung cancer. Clin Lung Cancer2021; 22: 268–273.
31.
KroemerGGalluzziLKeppO, et al.Immunogenic cell death in cancer therapy. Annu Rev Immunol2013; 31: 51–72.
32.
EspositoACriscitielloCCuriglianoG. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications. Curr Opin Oncol2015; 27: 445–451.
33.
BrahmerJReckampKLBaasP, et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med2015; 373: 123–135.
34.
EggermontAMMBlankCUMandalaM, et al.Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol2021; 22: 643–654.
35.
HellmannMDPaz-AresLBernabe CaroR, et al.Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med2019; 381: 2020–2031.
36.
WeberJSKahlerKCHauschildA. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol2012; 30: 2691–2697.
37.
TangSQTangLLMaoYP, et al.The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients. Cancer Res Treat2021; 53: 339–354.
38.
ShivajiUNJefferyLGuiX, et al.Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Therap Adv Gastroenterol2019; 12: 1756284819884196.
39.
LuoJMartucciVLQuandtZ, et al.Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer. Clin Cancer Res2021; 27: 5131–5140.
40.
HolsteadRGKartoloBAHopmanWM, et al.Impact of the development of immune related adverse events in metastatic melanoma treated with PD −1 inhibitors. Melanoma Res2021; 31: 258–263.
41.
ShahbarAAlshamraniMAseeriM, et al.Safety and discontinuation rate of immune checkpoint inhibitors used in patients with solid and hematological malignancies. A population based retrospective analysis. J Oncol Pharm Pract2022; 28: 771–776.
42.
DolladilleCEderhySSassierM, et al.Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol2020; 6: 865–871.
43.
SchneiderBJNaidooJSantomassoBD, et al.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol2021; 39: 4073–4126.
44.
KotwalAKottschadeLRyderM. PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients. Thyroid2020; 30: 177–184.
45.
DasSJohnsonDB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer2019; 7: 06.
46.
PercikRLielYUrbanD, et al.Thyroid dysfunction and survival in cancer patients treated with immune checkpoint inhibitors: analyses from a large single tertiary cancer center database. Acta Oncol2021; 60: 1466–1471.
47.
ClinicalTrials.gov [Internet]. PD-1 immune checkpoint inhibitors and immune-related adverse events: a cohort study, identifier: NCT04115410, https://clinicaltrials.gov/ct2/show/NCT04115410 (2022, accessed July 19, 2022).
48.
ClinicalTrials.gov [Internet]. Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma (ICI-RT-1), Identifier: NCT04419441, https://clinicaltrials.gov/ct2/show/NCT04419441 (2022, accessed July 19, 2022).
49.
ClinicalTrials.gov [Internet]. Immune Checkpoint Inhibitors Monitoring of Adverse Drug ReAction (CHIMeRA), Identifier: NCT03492242, https://clinicaltrials.gov/ct2/show/NCT03492242 (2022, accessed July 19, 2022).
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
